Company builders leveraging smart capital through SPVs

Our experienced team and advisors have extensive relationships with both potential portfolio companies and purchasers for exits in the Advanced Therapy space, providing global coverage and invaluable expertise in key Advanced Therapy developments worldwide.

We prioritize early-stage companies and founders driving innovation in Advanced Therapy technologies, aiming to reduce costs, save time, and enhance accessibility. Our tech-focused strategy capitalizes on our global team's unique strenghts and extensive industry experience, granting us a competitive edge in a less saturated market.  

We focus on Advanced Therapy related tools and enabling technologies, including critical reagents, assays, and diagnostics. Additionally, we invest in systems for the manufacturing and logistics supply chain, analytical technologies, and data capture (raw material, in-process, and final release). Machine learning and artificial intelligence are also key areas of our investment focus. 

We are structured as an operating corporation with SPVs which take an active business interest in all our investments, ensuring hands-on engagement and value creation. Our objective is to build a diversified portfolio of SPVs across categories of tools and technologies in CGT.

Altius Bioventures Capital commits its full resources to every investment, building trust and aligning values with tools and technologies companies long before a collaboration begins. Our ongoing engagement enhances the potential for higher-value exits.

Altius Bioventures Capital offers a unique team of experienced entrepreneurs, investors, and advisors, to drive growth and maximizes value for portfolio companies. Each portfolio SPV has an Altius partner assigned, and our global team of advisors enables founders to build and scale. 

Our approach emphasizes rigorous methods, validation, and thorough data analysis for evaluating potential investments and managing portfolios. We use a structured process to validate opportunities, employing a robust risk mitigation model.

Our commitment goes beyond financial returns—we actively support businesses that reflect a rich mosaic of backgrounds, perspectives, and experiences, fostering innovation, equity, and long-term impact across the advanced therapies landscape.